Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96L15

UPID:
NAR5_HUMAN

ALTERNATIVE NAMES:
ADP-ribosyltransferase C2 and C3 toxin-like 5; Mono(ADP-ribosyl)transferase 5; NAD(P)(+)--arginine ADP-ribosyltransferase 5

ALTERNATIVE UPACC:
Q96L15; C9IYG7; Q6UX84; Q86W02

BACKGROUND:
Ecto-ADP-ribosyltransferase 5, with its aliases including Mono(ADP-ribosyl)transferase 5 and NAD(P)(+)--arginine ADP-ribosyltransferase 5, is integral to the post-translational modification of proteins through ADP-ribosylation. This process is essential for regulating protein function and signaling pathways within the cell.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Ecto-ADP-ribosyltransferase 5 holds promise for identifying novel therapeutic approaches. As this protein is pivotal in cellular signaling and regulation, targeting it could lead to innovative treatments for diseases where these processes are disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.